IBRX
NASDAQImmunityBio Inc.
Website
News25/Ratings6
News · 26 weeks70+60%
2025-10-262026-04-19
Mix4190d
- Other20(49%)
- Insider12(29%)
- SEC Filings7(17%)
- Earnings1(2%)
- Analyst1(2%)
Latest news
25 items- PRImmunityBio Announces ANKTIVA® Is Now Available in Saudi Arabia for Bladder and Lung Cancer Patients; Market Entry Achieved Within Two Months of MENA PartnershipANKTIVA approved for patients with certain indications of non-muscle invasive bladder cancer and non-small cell lung cancer Commercial availability achieved within two months of announcing MENA partnership with Biopharma and Cigalah Healthcare First patients to be dosed have been identified and will soon receive initial ANKTIVA treatment ImmunityBio, Inc. ((IBRX), a commercial-stage immunotherapy company, today announced that ANKTIVA® (nogapendekin alfa inbakicept) is now commercially available in Saudi Arabia. Initial patients have been identified for treatment across both approved bladder and lung cancer indications in the Kingdom: In combination with Bacillus Calmette-Guérin
- SECImmunityBio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - ImmunityBio, Inc. (0001326110) (Filer)
- PRImmunityBio Reports Net Product Revenue Increased Nearly 2.7 Times Year-Over-Year to Record $44 Million in Q1 2026 and $381 Million in Cash and Marketable SecuritiesPreliminary Q1 2026 net product revenue of approximately $44.2 million, representing an ~168% year-over-year increase compared with Q1 2025 Consistent quarter-over quarter revenue growth since commercial launch, reflecting continued adoption of ANKTIVA® by U.S. urologists Full-year 2025 net product revenue of $113 million, a 700% increase over full-year 2024, as reported in the Company's Form 10-K ANKTIVA Unit Growth: 168% increase in unit sales volume in Q1 2026 compared to Q1 2025 ANKTIVA is now approved or authorized across five regulatory jurisdictions, representing approximately 34 countries NCCN Clinical Practice Guidelines updated in March 2026 to include ANKTIVA plus
- SECImmunityBio Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - ImmunityBio, Inc. (0001326110) (Filer)
- PRImmunityBio Addresses FDA Correspondence and Reaffirms Commitment to Advertising ComplianceCompany initiated a comprehensive review of promotional materials and is implementing enhanced advertising compliance measures, including expanded promotional review protocols, executive training, and external regulatory oversight Company has removed the identified podcast from its corporate website and formally requested its removal from all third-party hosting platforms Company confirmed that the television advertisement cited in the FDA correspondence was never broadcast, aired, or disseminated to the public ImmunityBio, Inc. ((IBRX), a commercial-stage immunotherapy company, today announced it has submitted a comprehensive response to the U.S. Food and Drug Administration (FDA
- INSIDERSEC Form 4 filed by Soon-Shiong Patrick4 - ImmunityBio, Inc. (0001326110) (Issuer)
- SECImmunityBio Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Other Events, Regulation FD Disclosure8-K - ImmunityBio, Inc. (0001326110) (Filer)
- PRImmunityBio Strengthens Balance Sheet with $100 Million of Financing Transactions Including $75 Million of Non-Dilutive Financing to Support Global Expansion and Advancement of Broader Immunotherapy PipelineImmunityBio to receive $75 million in non-dilutive funding under existing Revenue Interest Purchase Agreement (RIPA) with Oberland Capital, bringing total committed capital to $375 million Simultaneously conversion of $25 million of the outstanding promissory note held by Nant Capital, an entity affiliated with Executive Chairman bolstering ImmunityBio's balance sheet with reduction in the debt Proceeds strengthen ImmunityBio's balance sheet and support global expansion following recent approvals, while advancing company's broader immunotherapy pipeline ImmunityBio, Inc. ((IBRX), a vertically integrated, commercial-stage immunotherapy company, today announced it has secured $75 mi
- PRImmunityBio Confirms Statistical Power in Pivotal Randomized BCG-Naïve NMIBC Trial to Detect Clinically Meaningful Differences Between ANKTIVA® Plus BCG Versus BCG Alone; Supplemental BLA Submission on Track for 2026The QUILT-2.005 randomized clinical trial is on track for final analysis and supplemental Biologics License Application (BLA) submission in 2026 for the BCG-naïve NMIBC carcinoma in situ with or without papillary indication with no additional enrollment required The Independent Data Monitoring Committee (IDMC) confirmed that the fully enrolled study (N=366) is adequately powered to detect the pre-specified difference in complete response rate between the experimental and control arms, and that no additional enrollment is required A planned interim analysis was conducted by the IDMC per the protocol once 50% of enrolled patients (N=183) in Cohort A were evaluable for the primary e
- PRImmunityBio Announces Approval in Macau SAR, China for ANKTIVA® in BCG-Unresponsive NMIBC with CIS ± Papillary TumorsMacau SAR, China regulator grants approval for ANKTIVA® (nogapendekin alfa inbakicept-pmln) in patients with BCG-unresponsive NMIBC with CIS ± papillary tumors Authorization follows a reliance-based review referencing prior FDA and EMA decisions First ANKTIVA authorization in Asia, supporting ongoing global expansion across 34 countries and territories ImmunityBio, Inc. ((IBRX), today announced that the Pharmaceutical Administration Bureau (ISAF) of the Macau Special Administrative Region of the People's Republic of China has granted regulatory approval for ANKTIVA® (nogapendekin alfa inbakicept-pmln). The approval establishes ANKTIVA's initial presence in Asia and reflects the
- PRImmunityBio Announces NCCN® Clinical Practice Guidelines in Oncology Have Been Updated to Include ANKTIVA® Plus BCG for Patients With BCG-Unresponsive NMIBC With Papillary-Only DiseaseRecommendation is based on peer-reviewed clinical data supporting long-term effectiveness and safety durability in patients with papillary-only disease treated with ANKTIVA plus BCG1. ImmunityBio, Inc. ((IBRX), a commercial-stage immunotherapy company, today announced that the National Comprehensive Cancer Network (NCCN®) has updated its 2026 NCCN Clinical Practice Guidelines in Oncology for Bladder Cancer to include ANKTIVA® (nogapendekin alfa inbakicept-pmln) in combination with Bacillus Calmette-Guérin (BCG) for the treatment of patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with papillary-only disease. This update expands previous NCCN clinical guideline r
- PRImmunityBio Achieves Milestone with Large-Scale NK Cell Production and Cryopreservation from Over 60 Healthy and Cancer DonorsMethods developed and validated to establish the "World Bank of NK Cells" from healthy donors and cancer patients Single apheresis yields up to 5 billion (5×109) highly pure activated memory cytokine-enhanced NK cells (M-ceNK), providing up to 8-10 doses of M-ceNK product per patient Manufacturing and cryo-banking process established with finished dosage form of M-ceNK cells available within 12 days from apheresis M-ceNK cells successfully cryopreserved with demonstration of retained cytotoxicity against multiple tumor cell lines Methods now established in readiness for manufacturing in AI-driven automated robotic systems (NANT Leonardo) Combination of M-ceNK with ANKTIVA® s
- ANALYSTBTIG Research resumed coverage on ImmunityBio with a new price targetBTIG Research resumed coverage of ImmunityBio with a rating of Buy and set a new price target of $13.00
- PRImmunityBio to Provide a Business Update and Review Financial Results for FY 2025 on Tuesday, March 3, 2026ImmunityBio, Inc. ((IBRX), today announced that it will host a live conference call at 1:30 p.m. Pacific Time on Tuesday, March 3, 2026, to provide a business update, including progress across the company's clinical trial pipeline, and to review financial results for the year ended December 31, 2025. Conference Call Details The conference call will begin at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) on Tuesday, March 3, 2026. Interested parties may access the conference call through our Investor Relations website, ir.immunitybio.com, under Company — Events & Presentations. Alternatively, individuals can access the call by dialing 1-844-539-3703 or 1-412-652-1273 (internationally).
- INSIDERDirector Simon Barry J. sold $900,788 worth of shares (75,000 units at $12.01), decreasing direct ownership by 3% to 2,850,821 units (SEC Form 4)4 - ImmunityBio, Inc. (0001326110) (Issuer)
- PRImmunityBio Completes Enrollment in Pivotal Randomized Trial Evaluating ANKTIVA® Plus BCG Versus BCG Alone in BCG-Naïve Non-Muscle Invasive Bladder Cancer Carcinoma In SituStudy fully enrolled ahead of schedule, with 366 of 366 BCG-naïve NMIBC patients randomized to receive BCG alone or ANKTIVA plus BCG Interim analysis requested by the FDA demonstrated a statistically significant improvement in duration of complete response with ANKTIVA plus BCG, with no significant safety signals observed Company anticipates submitting a biologics license application (BLA) to the U.S. FDA by Q4 2026 Expanded access program (EAP) of recombinant BCG is ongoing, with 580 patients currently enrolled throughout the U.S. ImmunityBio ((IBRX), a commercial-stage immunotherapy company, today announced completion of enrollment in its Phase 2 clinical trial evaluating ANK
- PRImmuno-Oncology Investments Accelerate as Pipeline Catalysts Multiply in 2026Issued on behalf of Oncolytics Biotech Inc.VANCOUVER, BC, Feb. 25, 2026 /CNW/ -- Equity Insider News Commentary, The immuno-oncology market is forecast to grow from $65.22 billion in 2025 to $170.19 billion by 2032, fueled by checkpoint inhibitors, CAR-T cell therapy, and cancer vaccines[1]. Five companies positioned at the forefront of this expansion include Oncolytics Biotech (NASDAQ:ONCY), ImmunityBio (NASDAQ:IBRX), CRISPR Therapeutics (NASDAQ:CRSP), BioNTech (NASDAQ:BNTX), and Novocure (NASDAQ:NVCR). The broader oncology market is projected to nearly triple from $279.98 bill
- INSIDERDirector Selecky Christobel exercised 25,000 shares at a strike of $2.98 and sold $250,000 worth of shares (25,000 units at $10.00) (SEC Form 4)4 - ImmunityBio, Inc. (0001326110) (Issuer)
- INSIDEROfficer Soon-Shiong Patrick converted options into 114,329 shares and covered exercise/tax liability with 58,170 shares, increasing direct ownership by 0.19% to 29,757,911 units (SEC Form 4)4 - ImmunityBio, Inc. (0001326110) (Issuer)
- INSIDERChief Financial Officer Sachs David C. converted options into 40,650 shares and covered exercise/tax liability with 20,682 shares, increasing direct ownership by 7% to 300,143 units (SEC Form 4)4 - ImmunityBio, Inc. (0001326110) (Issuer)
- INSIDERChief Accounting Officer Lauer Regan J converted options into 4,065 shares and covered exercise/tax liability with 1,673 shares, increasing direct ownership by 2% to 115,875 units (SEC Form 4)4 - ImmunityBio, Inc. (0001326110) (Issuer)
- INSIDERCEO & President Adcock Richard converted options into 152,439 shares and covered exercise/tax liability with 77,560 shares, increasing direct ownership by 15% to 560,344 units (SEC Form 4)4 - ImmunityBio, Inc. (0001326110) (Issuer)
- INSIDERDirector Simon Barry J. converted options into 15,243 shares, covered exercise/tax liability with 6,026 shares and sold $1,783,602 worth of shares (175,000 units at $10.19), decreasing direct ownership by 5% to 2,925,821 units (SEC Form 4)4 - ImmunityBio, Inc. (0001326110) (Issuer)
- SECSEC Form 10-K filed by ImmunityBio Inc.10-K - ImmunityBio, Inc. (0001326110) (Filer)
- PRImmunityBio Founder Dr. Patrick Soon-Shiong to Speak at Milken Institute and Richard Nixon Foundation "Cancer 2035: A Roadmap for the Future" SummitDr. Soon-Shiong joins Nobel laureates, former NIH directors, and leading oncology pioneers in Washington, D.C. to chart a path toward defeating cancer by 2035, with the discussion streamed live at Cancer 2035: A Roadmap for the Future Summit ImmunityBio, Inc. (NASDAQ:IBRX), a commercial-stage biotechnology company pioneering next-generation immunotherapies, today announced that its Founder, Executive Chairman, and Global Chief Scientific and Medical Officer, Dr. Patrick Soon-Shiong, will participate as a featured speaker at "Cancer 2035: A Roadmap for the Future," a landmark summit co-hosted by the Milken Institute and the Richard Nixon Foundation in Washington, D.C. on February 23–24, 20